Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Recruiting · NCT06058234 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
View the official record on ClinicalTrials.gov →Interventions studied
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
What this trial is about
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
Exclusion criteria
- none
Where it is running
1 location listed across 1 US state.
- Centers for Medicare and Medicaid Services - Baltimore, Maryland, United States